Poseida Therapeutics Statistics
Share Statistics
Poseida Therapeutics has 97.47M shares outstanding. The number of shares has increased by 1.01% in one year.
| Shares Outstanding | 97.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.34% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 64.70M |
| Failed to Deliver (FTD) Shares | 20 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 3.59M, so 3.68% of the outstanding shares have been sold short.
| Short Interest | 3.59M |
| Short % of Shares Out | 3.68% |
| Short % of Float | 5.32% |
| Short Ratio (days to cover) | 1.49 |
Valuation Ratios
The PE ratio is -2.46 and the forward PE ratio is -2.2.
| PE Ratio | -2.46 |
| Forward PE | -2.2 |
| PS Ratio | 4.68 |
| Forward PS | 21 |
| PB Ratio | 2.92 |
| P/FCF Ratio | -3.18 |
| PEG Ratio | n/a |
Enterprise Valuation
Poseida Therapeutics Inc. has an Enterprise Value (EV) of 388.44M.
| EV / Earnings | -3.15 |
| EV / Sales | 6 |
| EV / EBITDA | -3.56 |
| EV / EBIT | -3 |
| EV / FCF | -4.08 |
Financial Position
The company has a current ratio of 3.18, with a Debt / Equity ratio of 0.71.
| Current Ratio | 3.18 |
| Quick Ratio | 3.18 |
| Debt / Equity | 0.71 |
| Total Debt / Capitalization | 41.38 |
| Cash Flow / Debt | -1.26 |
| Interest Coverage | -14.94 |
Financial Efficiency
Return on equity (ROE) is -1.19% and return on capital (ROIC) is -68.54%.
| Return on Equity (ROE) | -1.19% |
| Return on Assets (ROA) | -0.45% |
| Return on Capital (ROIC) | -68.54% |
| Revenue Per Employee | 184.87K |
| Profits Per Employee | -352.66K |
| Employee Count | 350 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 107.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 211.48% in the last 52 weeks. The beta is 0.54, so Poseida Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.54 |
| 52-Week Price Change | 211.48% |
| 50-Day Moving Average | 6.52 |
| 200-Day Moving Average | 3.79 |
| Relative Strength Index (RSI) | 75.33 |
| Average Volume (20 Days) | 1.71M |
Income Statement
In the last 12 months, Poseida Therapeutics had revenue of 64.70M and earned -123.43M in profits. Earnings per share was -1.37.
| Revenue | 64.70M |
| Gross Profit | -92.07M |
| Operating Income | -129.50M |
| Net Income | -123.43M |
| EBITDA | -109.04M |
| EBIT | -129.50M |
| Earnings Per Share (EPS) | -1.37 |
Balance Sheet
The company has 44.47M in cash and 85.42M in debt, giving a net cash position of -40.95M.
| Cash & Cash Equivalents | 44.47M |
| Total Debt | 85.42M |
| Net Cash | -40.95M |
| Retained Earnings | -594.29M |
| Total Assets | 293.58M |
| Working Capital | 172.44M |
Cash Flow
In the last 12 months, operating cash flow was -92.17M and capital expenditures -3.07M, giving a free cash flow of -95.23M.
| Operating Cash Flow | -92.17M |
| Capital Expenditures | -3.07M |
| Free Cash Flow | -95.23M |
| FCF Per Share | -1.06 |
Margins
Gross margin is -142.29%, with operating and profit margins of -200.15% and -190.76%.
| Gross Margin | -142.29% |
| Operating Margin | -200.15% |
| Pretax Margin | -190.6% |
| Profit Margin | -190.76% |
| EBITDA Margin | -168.52% |
| EBIT Margin | -200.15% |
| FCF Margin | -147.18% |
Dividends & Yields
PSTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.42% |
| FCF Yield | -10.29% |
Analyst Forecast
The average price target for PSTX is $9, which is -5.3% lower than the current price. The consensus rating is "Hold".
| Price Target | $9 |
| Price Target Difference | -5.3% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.34 |
| Piotroski F-Score | 4 |